266 related articles for article (PubMed ID: 28447476)
1. MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.
Marinova D; Gonzalo-Asensio J; Aguilo N; Martin C
Expert Rev Vaccines; 2017 Jun; 16(6):565-576. PubMed ID: 28447476
[TBL] [Abstract][Full Text] [Related]
2. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.
Arbues A; Aguilo JI; Gonzalo-Asensio J; Marinova D; Uranga S; Puentes E; Fernandez C; Parra A; Cardona PJ; Vilaplana C; Ausina V; Williams A; Clark S; Malaga W; Guilhot C; Gicquel B; Martin C
Vaccine; 2013 Oct; 31(42):4867-73. PubMed ID: 23965219
[TBL] [Abstract][Full Text] [Related]
3. Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
Clark S; Lanni F; Marinova D; Rayner E; Martin C; Williams A
J Infect Dis; 2017 Sep; 216(5):525-533. PubMed ID: 28329234
[TBL] [Abstract][Full Text] [Related]
4. MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG.
Martín C; Marinova D; Aguiló N; Gonzalo-Asensio J
Vaccine; 2021 Dec; 39(50):7277-7285. PubMed ID: 34238608
[TBL] [Abstract][Full Text] [Related]
5. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
6. New tuberculosis vaccines.
Martín Montañés C; Gicquel B
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
[TBL] [Abstract][Full Text] [Related]
7. MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic.
Gonzalo-Asensio J; Marinova D; Martin C; Aguilo N
Front Immunol; 2017; 8():1803. PubMed ID: 29326700
[TBL] [Abstract][Full Text] [Related]
8. Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice.
Solans L; Uranga S; Aguilo N; Arnal C; Gomez AB; Monzon M; Badiola JJ; Gicquel B; Martin C
Vaccine; 2014 Sep; 32(40):5192-7. PubMed ID: 25066740
[TBL] [Abstract][Full Text] [Related]
9. Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro-American genetic background confers optimal vaccine potential.
Pérez I; Uranga S; Sayes F; Frigui W; Samper S; Arbués A; Aguiló N; Brosch R; Martín C; Gonzalo-Asensio J
EBioMedicine; 2020 May; 55():102761. PubMed ID: 32361249
[TBL] [Abstract][Full Text] [Related]
10. MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.
Aguilo N; Uranga S; Marinova D; Monzon M; Badiola J; Martin C
Tuberculosis (Edinb); 2016 Jan; 96():71-4. PubMed ID: 26786657
[TBL] [Abstract][Full Text] [Related]
11. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates.
Méndez-Samperio P
Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842
[TBL] [Abstract][Full Text] [Related]
12. Current status of new tuberculosis vaccine in children.
Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer.
Alvarez-Arguedas S; Uranga S; Martín M; Elizalde J; Gomez AB; Julián E; Nardelli-Haefliger D; Martín C; Aguilo N
Transl Res; 2018 Jul; 197():32-42. PubMed ID: 29702078
[TBL] [Abstract][Full Text] [Related]
14. A review of clinical models for the evaluation of human TB vaccines.
O'Shea MK; McShane H
Hum Vaccin Immunother; 2016 May; 12(5):1177-87. PubMed ID: 26810964
[TBL] [Abstract][Full Text] [Related]
15. [When will the new tuberculosis vaccine appear?].
Koroliuk AM; Zazimko LA; Petrovskiĭ SV
Zh Mikrobiol Epidemiol Immunobiol; 2015; (1):86-94. PubMed ID: 25842959
[TBL] [Abstract][Full Text] [Related]
16. The quest for a new vaccine against tuberculosis.
Delogu G; Fadda G
J Infect Dev Ctries; 2009 Feb; 3(1):5-15. PubMed ID: 19749443
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis vaccine development: Shifting focus amid increasing development challenges.
Graves AJ; Hokey DA
Hum Vaccin Immunother; 2015; 11(8):1910-6. PubMed ID: 26125249
[TBL] [Abstract][Full Text] [Related]
18. The second Geneva Consensus: Recommendations for novel live TB vaccines.
Walker KB; Brennan MJ; Ho MM; Eskola J; Thiry G; Sadoff J; Dobbelaer R; Grode L; Liu MA; Fruth U; Lambert PH
Vaccine; 2010 Mar; 28(11):2259-70. PubMed ID: 20074686
[TBL] [Abstract][Full Text] [Related]
19. Successes and failures in human tuberculosis vaccine development.
Zenteno-Cuevas R
Expert Opin Biol Ther; 2017 Dec; 17(12):1481-1491. PubMed ID: 28927311
[TBL] [Abstract][Full Text] [Related]
20. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis.
Aguilo N; Gonzalo-Asensio J; Alvarez-Arguedas S; Marinova D; Gomez AB; Uranga S; Spallek R; Singh M; Audran R; Spertini F; Martin C
Nat Commun; 2017 Jul; 8():16085. PubMed ID: 28706226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
